Insulin-like growth factor factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling

Cancer Biology and Therapy

Volumn 5, Issue 10, 2006, Pages 1408-1414

  Grimberg, Adda ^a,d   Coleman, Carrie M ^a   Shi, Zonggao ^a   Burns, Timothy F ^a,b   MacLachlan, Timothy K ^a,c   Wang, Wenge ^a   El Deiry, Wafik S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GENZYME CORPORATION   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

E6; Extracellular signal regulated kinase; Insulin like growth factor binding protein 2; Insulin like growth factor I; p53; Prostate cancer; Transcription

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P53; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL GROWTH; CELL TRANSFORMATION; CONTROLLED STUDY; DNA DAMAGE; FEMALE; GENE ACTIVATION; GENE REPRESSION; GENE SEQUENCE; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG CANCER; MITOGENESIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; WART VIRUS;

EID: 33751084057     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.10.3455     Document Type: Article

References (50)

1. Guimaraes DP, Hainaut P. TP53: A key gene in human cancer. Biochimie 2002; 84:83-93.
2. Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Human Mutn 2003; 21:313-20.
3. Parant JM, Lozano G. Disrupting TP53 in mouse models of human cancers. Human Mutn 2003; 21:321-6.
4. Giono LE, Manfredi JJ. The p53 tumor suppressor participates in multiple cell cycle check-points. J Cell Physiol 2006; 209:13-20.
5. Oren M. Decision making by p53: Life, death and cancer. Cell Death Differ 2003; 10:431-442.
6. Balint EE, Vousden KH. Activation and activities of the p53 tumour suppressor protein. Brit J Cancer 2001; 85:1813-23.
7. El-Deiry WS. Regulation of p53 downstream genes. Sem Cancer Biol 1998; 8:345-57.
8. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995; 377:646-9.
9. Bourdon JC, Deguin-Chambon V, Lelong JC, Dessen P, May P, Debuire B, May E. Further characterisation of the p53 responsive element-identification of new candidate genes for trans-activation by p53. Oncogene 1997; 14:85-94.
10. Hanafusa T, Shinji T, Shiraha H, Nouso K, Iwasaki Y, Yumoto E, Ono T, Koide N. Functional promoter upstream p53 regulatory sequence of IGFBP3 that is silenced by tumor specific methylation. BMC Cancer 2005; 5:9.
11. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000; 183:1-9.
12. Grimberg A. p53 and IGFBP-3: Apoptosis and cancer protection. Molec Genet Metabol 2000; 70:85-98.
13. Grimberg A, Liu B, Bannerman P, El-Deiry WS, Cohen P. IGFBP-3 mediates p53-induced apoptosis during serum starvation. Internatl J Oncol 2002; 21:327-35.
14. Pintar JE, Cerro JA, Wood TL. Genetic approaches to the function of insulin-like growth factor-binding proteins during rodent development. Horm Res 1996; 45:172-7.
15. Wu GS, El-Deiry WS. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2. Clin Cancer Res 1996; 2:623-33.
16. Coleman CM, Grimberg A. Alterations in the expression of insulin-like growth factors and their binding proteins in lung cancer. Methods Mol Med 2003; 74:167-86.
17. Burns TF, Bernhard EJ, El-Deiry WS. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene 2001; 20:4601-12.
18. Grimberg A, Coleman CM, Burns TF, Himelstein BP, Koch CJ, Cohen P, El-Deiry WS. p53-Dependent and p53-independent induction of insulin-like growth factor binding protein-3 by deoxyribonucleic acid damage and hypoxia. J Clin Endocrinol Metab 2005; 90:3568-74.
19. MacLachlan TK, El-Deiry WS. Apoptotic threshold is lowered by p53 transactivation of caspase-6. Proc Natl Acad Sci USA 2002; 99:9492-7.
20. Takimoto R, El-Deiry WS. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000; 19:1735-43.
21. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-25.
22. Wang W, Takimoto R, Rastinejad F, El-Deiry WS. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 2003; 23:2171-81.
23. Thomas M, Matlashewski G, Pim D, Banks L. Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation. Oncogene 1996; 13:265-73.
24. Thomas MC, Chiang CM. E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Molec Cell 2005; 17:251-64.
25. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992; 1:45-9.
26. Binkert C, Landwehr J, Mary JL, Schwander J, Heinrich G. Cloning, sequence analysis and expression of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2). EMBO J 1989; 8:2497-502.
27. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275:1943-7.
28. Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 1999; 20:761-87.
29. Schedlich LJ, Young TF, Firth SM, Baxter RC. Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J Biol Chem 1998; 273:18347-52.
30. Ferry RJ, Katz LEL, Grimberg A, Cohen P, Weinzimer S. Cellular actions of insulin-like growth factor binding proteins. Horm Metab Res 1999; 31:192-202.
31. Werner H, Karnieli E, Rauscher FJ, LeRoith D. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 1996; 93:8318-23.
32. Zhang L, Zhan Q, Zhan S, Kashanchi F, Fornace Jr AJ, Seth P, Helman LJ. p53 regulates human insulin-like growth factor II gene expression through active P4 promoter in rhabdomyosarcoma cells. DNA Cell Biol 1998; 17:125-31.
33. Ohlsson C, Kley N, Werner H, LeRoith D. p53 regulates insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced tyrosine phosphorylation in an osteosarcoma cell line: Interaction between p53 and Sp1. Endocrinol 1998; 139:1101-7.
34. Prisco M, Hongo A, Rizzo MG, Sacchi A, Baserga R. The insulin-like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal. Molec Cell Biol 1997; 17:1084-92.
35. Lee YI, Han YJ, Lee SY, Lee YI, Park SK, Park YJ, Moon HB, Shin JH, Lee JH. Activation of insulin-like growth factor II signaling by mutant type p53: Physiological implications for potentiation of IGF-II signaling by p53 mutant 249. Mol Cell Endocrinol 2003; 203:51-63.
36. Grimberg A. Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther 2003; 2:630-5.
37. Grimberg A. Cancer. Adv Exp Med Biol 2005; 567:305-39.
38. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10:789-99.
39. Levine AJ, Feng Z, Mak TW, You H, Jin S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 2006; 20:267-75.
40. Schutt BS, Langkamp M, Rauschnabel U, Ranke MB, Elmlinger MW. Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol 2004; 32:859-68.
41. Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, Kolb HJ, Weber MM, Wolf E. Insulin-like growth factor-binding protein 2 in tumorigenesis: Protector or promoter? Cancer Res 2001; 61:8601-10.
42. Besnard V, Corroyer S, Trugnan G, Chadelat K, Nabeyrat E, Cazals V, Clement A. Distinct patterns of insulin-like growth factor binding protein (IGFBP)-2 and IGFBP-3 expression in oxidant exposed lung epithelial cells. Biochim Biophys Acta 2001; 1538:47-58.
43. Hoeflich A, Reisinger R, Schuett BS, Elmlinger MW, Russo VC, Vargas GA, Jehle PM, Lahm H, Renner-Muller I, Wolf E. Peri/nuclear localization of intact insulin-like growth factor binding protein-2 and a distinct carboxyl-terminal IGFBP-2 fragment in vivo. Biochem Biophys Res Commun 2004; 324:705-10.
44. Lee EJ, Mircean C, Shmulevich I, Wang H, Liu J, Niemisto A, Kavanagh JJ, Lee JH, Zhang W. Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Mol Cancer 2005; 4:7.
45. Miyake H, Hara I, Yamanaka K, Muramaki M, Gleave M, Eto H. Introduction of insulin-like growth factor binding protein-2 gene into human bladder cancer cells enhances their metastatic potential. Oncol Rep 2005; 13:341-5.
46. Hoeflich A, Fettscher O, Lahm H, Blum WF, Kolb HJ, Engelhardt D, Wolf E, Weber MM. Overexpression of insulin-like growth factor-binding protein-2 results in increased tumorigenic potential in Y-1 adrenocortical tumor cells. Cancer Res 2000; 60:834-8.
47. Chatterjee S, Park ES, Soloff MS. Proliferation of DU145 prostate cancer cells is inhibited by suppressing insulin-like growth factor binding protein-2. Int J Urol 2004; 11:876-84.
48. Hoeflich A, Nedbal S, Blum WF, Erhard M, Lahm H, Brem G, Kolb HJ, Wanke R, Wolf E. Growth inhibition in giant growth hormone transgenic mice by overexpression of insulin-like growth factor-binding protein-2. Endocrinol 2001; 142:1889-98.
49. Wood TL, Rogler LE, Czick ME, Schuller AG, Pintar JE. Selective alterations in organ sizes in mice with a targeted disruption of the insulin-like growth factor binding protein-2 gene. Molec Endocrinol 2000; 14:1472-82.
50. Ehrenborg E, Vilhelmsdotter S, Bajalica S, Larsson C, Stern I, Koch J, Brondum-Nielsen K, Luthman H. Structure and localization of the human insulin-like growth factor-binding protein 2 gene. Biochem Biophys Res Commun 1991; 176:1250-15.